Introduction
============

Heart failure (HF) is the second major cause of hospitalization in Brazil^[@r01]^. In the United States, 32 billion dollars will be spent during 2013^[@r02]^ with that syndrome. In addition, those patients\' quality of life is severely impaired. Despite the reduction in morbidity and mortality due to new drugs, that gain has not been uniform, and clinical outcome can be unfavorable. One of the mechanisms that can justify such differences is genetics.

The genetic influence, comprising all stages of the syndrome^[@r03]^, has been studied in the following phases: pre-installation^[@r04]^; development^[@r05]^; and clinical phase (disease natural history^[@r06]^ and therapeutic response^[@r07]^). Those results are controversial^[@r08]^ and the studies have been carried out in foreign populations; thus, their impact on the Brazilian population remains unclear.

The major mechanism of that genetic influence is via modulation of the activity of the sympathetic nervous (SNS) and renin-angiotensin-aldosterone (RAAS) systems, which promote cardiac remodeling and sodium and water retention, characteristics of HF. Variations in the activity of those systems would determine different pathophysiological responses, and, thus, varied clinical outcome.

Some genetic markers, the genetic polymorphisms (GP), have been identified and associated with the molecular processes of that neuro-humoral response, such as beta-adrenergic receptors^[@r07]^, angiotensin synthesis^[@r09]^, nitric oxide metabolism^[@r10]^, and angiotensin converting enzyme (ACE)^[@r04],[@r11]-[@r19]^. The later, object of this study, is the major agent of the RAAS.

Regarding RAAS, the major GP was the ACE Deletion/Insertion (DI) of 287 base pairs of the intron 16 (GPACE)^[@r20]^. The GPACE, especially the Deletion/Deletion (DD) genotype, was associated with the risk for HF^[@r21]^, mortality^[@r22]^, rejection to heart transplants^[@r23]^, and echocardiographic variations^[@r24]^. However, that relationship has not been observed in some publications^[@r11],[@r19],[@r25]^.

Published studies have controversial results and small sample sizes, and have been carried out in populations different from the Brazilian one, regarding geographical, epidemiological and ethnical aspects. In addition, patients with non-ischemic HF are usually underrepresented in studies on the topic, involving different pathophysiological mechanisms^[@r26]^and variable therapeutic responses^[@r27]^.

Thus, the present study aimed at determining the frequency of the GPACE variants and their relation with the clinical and echocardiographic outcomes of patients with non-ischemic HF.

Methods
=======

Study design
------------

This is a longitudinal study of a cohort of patients. Medical data were retrospectively and prospectively collected from their medical records, beginning at the patient\'s arrival at the HF Clinics of a university-affiliated hospital, from December 2009 to January 2012.

Patients
--------

This study consecutively selected 111 patients (67 men and 44 women) diagnosed with systolic non-ischemic HF, on a minimum 12-months follow-up. The major characteristics of the sample were as follows: mean age, 59.5 ± 1.3 years (range: 26 - 89 years); male prevalence (60.4%); and ethnical composition (white, 51.4%; black, 36.0%; others, 12.6%). The mean follow-up time was 64.9 ± 3.9 months.

Inclusion criteria
------------------

Patients with symptomatic non-ischemic HF, according to the Framingham criteria, and systolic ventricular dysfunction with ejection fraction ≤ 50% on two-dimensional echocardiography (Simpson\'s method) were considered eligible to the study.

Exclusion criteria
------------------

The presence of significant coronary arterial disease defined as coronary lesion ≥ 75% in two or more epicardial arteries or ≥ 75% in left main coronary artery^[@r28]^ led to exclusion from this study.

Heart failure etiology
----------------------

The HF etiologies were classified into four groups: idiopathic (36.0%); hypertensive (20.7%); alcoholic (18.9%); and others (24.3%). The diagnosis was established by the physician at the HF Clinics, according to previously described criteria^[@r29]^.

Clinical, laboratory and electrocardiographic parameters
--------------------------------------------------------

Clinical data were extracted from medical records. Skin color was defined by the attending physician and classified as white, black or others. The functional class was determined according to the New York Heart Association functional classification, at the beginning and end of follow-up.

Laboratory tests were periodically performed at the discretion of the attending physician. The most recently available exams were considered for analysis to express the patient\'s current clinical status.

All patients underwent electrocardiography (ECG), and were assessed regarding QRS duration, presence of left bundle-branch block (LBBB) and atrial fibrillation (AF).

Echocardiographic variables
---------------------------

The following parameters were assessed: left ventricular systolic diameter (LVSD); left ventricular diastolic diameter (LVDD); and left ventricular ejection fraction (LVEF). Echocardiography was performed by a medical team blinded to the patients\' genotypes. Two echocardiographies were performed, one at the beginning and another at the end of follow-up, with a mean interval between exams of 65.5 ± 4.3 months (range: 12 - 232 months), so that the evolution of those parameters could also be observed.

Genotyping
----------

The GPACE variants were analyzed from blood samples collected. After storage under a temperature of 5-15ºC, the samples were processed and the DNA extracted according to the salting out procedure^[@r30]^. After extraction, the polymorphism was genotyped by use of polymerase chain reaction (PCR) and classified as DD, DI or Insertion/Insertion (II).

Statistical Analysis
--------------------

All data obtained were analyzed by use of the statistical program Statistical Package for the Social Science for Mac (SPSS), version 21. In all tests, the rejection level of the null hypothesis was fixed as 0.05 or 5% (p \< 0.05) and the 95% confidence interval (CI) was used. The central trend measurements were expressed as mean ± standard deviation.

The following tests were used: chi-square, Student *t* test and analysis of variance (ANOVA).

The genotype and haplotype frequencies were tested for Hardy-Weinberg equilibrium^[@r31]^, by using the ARLEQUIN software, 2000 version.

The project was approved by the Committee on Ethics and Research of the Pedro Ernesto university-affiliated hospital (December 16th 2009). All patients provided written informed consent.

The present study was partially financed by the Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) after approval of the Inovacor project.

Results
=======

Genetic profile of the population studied
-----------------------------------------

In the population studied, the D allele occurred 163 times (73%), while the I allele, 59 times (27%). Regarding genotypes, 57 (51.4%) were classified as DD, 49 (44.1%) as DI, and only 5 (4.5%) as II. The population studied was in Hardy-Weinberg equilibrium.

Characteristics of the population sample
----------------------------------------

There was a predominance of the male sex and white individuals, and a high incidence of systemic arterial hypertension (SAH) and smoking. However, the prevalences of diabetes mellitus and dyslipidemia were relatively low. No significant difference in the genotypes was observed for any of the clinical or laboratory characteristics assessed ([Table 1](#t01){ref-type="table"}).

###### 

Clinical characteristics of the population studied according to the genetic polymorphisms of the angiotensin-converting enzyme

  **Clinical variable[\*](#t01-fn01){ref-type="table-fn"}**   **Mean**      **DD (n = 57)**   **DI (n = 49)**   **II (n = 5)**   **Statistical test**   **p Value**
  ----------------------------------------------------------- ------------- ----------------- ----------------- ---------------- ---------------------- -------------
  Follow-up (months)                                          64.9 ± 3.9    65.2 ± 6.1        64.7 ± 5.1        63.6 ± 13.6      F = 0.004              0.996
  HF duration (months)                                        97.0 ±6.9     89.9 ± 7.6        107.6 ± 12.7      73.4 ± 15.0      F = 1.067              0.348
  Age (years)                                                 59.5 ±1.3     61.1 ± 12.6       57.8 ± 14.6       57.2 ± 10.7      F = 0.852              0.429
  Male gender                                                 67 (60.4)     35 (61.4)         27 (56.3)         4 (80.0)         X^2^ = 1.61            0.560
  **Ethnicity**                                                                                                                                         
  White                                                       57 (51.4)     27 (47.4)         25 (52.1)         4 (80.0)         X^2^ = 2.158           0.707
  Black                                                       40 (36)       22 (38.6)         17 (35.4)         1 (20.0)                                
  Others                                                      14 (12.6)     8 (14.0)          6 (12.5)          0 (0)                                   
  BMI (kg/m^2^)                                               26.1±0.6      26.0 ± 0.9        26.1 ± 0.8        28.0 ± 2.2       0.231                  0.794
  Arterial hypertension                                       78 (70.3)     41 (71.9)         33 (68.8)         4 (80.0)         X^2^ = 0.338           0.845
  Diabetes mellitus                                           24 (21.6)     13 (22.8)         9 (18.8)          2 (40.0)         X^2^ = 1.267           0.531
  Anemia                                                      17 (15.3)     11 (19.3)         6 (12.5)          0                X^2^ = 1.879           0.391
  Dyslipidemia                                                43 (38.7)     23 (40.4)         17 (35.4)         3 (60.0)         X^2^ = 1.228           0.541
  Atrial fibrillation                                         22 (19.8)     12 (21.1)         8 (16.7)          2 (40.0)         X^2^ = 1.751           0.781
  Current smoker                                              7 (6.3)       8 (14.3)          3 (6.3)           2 (40.0)         X^2^ = 7.350           0.775
  Former smoker                                               45 (40.5)     24 (42.1)         19 (39.6)         1 (20.0)                                
  Former smoker                                               21 (19.1)     8 (14.3)          10 (20.8)         3 (60.0)         X^2^ = 7.350           0.118
  Former alcoholic                                            42 (38.2)     20 (35.7)         20 (41.7)         1 (20.0)                                
  initial NYHA[\*\*](#t01-fn02){ref-type="table-fn"} I        25 (22.5)     13 (22.8)         12 (25.0)         0 (0)            X^2^ = 5.400           0.714
  initial NYHA[\*\*](#t01-fn02){ref-type="table-fn"} II       51 (45.9)     25 (43.9)         22 (45.8)         4 (80.0)                                
  initial NYHA[\*\*](#t01-fn02){ref-type="table-fn"} III      23 (20.7)     14 (24.6)         8 (16.7)          1 (20.0)                                
  initial NYHA[\*\*](#t01-fn02){ref-type="table-fn"} IV       3 (9.9)       5 (8.8)           6 (12.5)          0 (0)                                   
  mean initial NYHA                                           2.18 ± 0.09   2.19 ± 0.12       2.17 ± 0.14       2.20 ± 0.20      F = 0.012              0.988
  final NYHA I                                                41 (36.9)     19 (33.3)         19 (39.6)         3 (60.0)         X^2^ = 7.664           0.264
  final NYHA II                                               53 (47.7)     26 (45.6)         25 (52.1)         2 (40.0)                                
  final NYHA III                                              14 (12.6)     11 (19.3)         3 (6.1)           0 (0)                                   
  final NYHA IV                                               3 (2.7)       1 (1.8)           2 (4.2)           0 (0)                                   
  mean final NYHA                                             1.81 ± 0.07   1.89 ± 0.10       1.76 ± 0.11       1.40 ± 0.25      F = 1.224              0.298
  Hemoglobin (g/dL)                                           14.2 ± 1.3    12.57 ± 1.94      16.02 ± 20.28     14.2 ± 1.30      F = 0.834              0.437
  Creatinine (mg/dL)                                          1.03 ± 0.18   1.03 ± 0.31       1.12 ± 0.18       0.40 ± 0.24      F = 0.336              0.715
  Uric acid (mg/dL)                                           6.5 ± 0.2     6.51 ± 2.20       6.52 ± 2.01       5.2 ± 1.48       F = 0.92               0.402
  Sodium (mEq/L)                                              138.9 ± 0.3   138.43 ± 3.60     139.40 ± 2.83     139.40 ± 2.41    F = 1.213              0.302
  Potassium (mEq/L)                                           4.1 ± 0.1     4.18 ± 0.66       4.02 ± 0.64       4.00 ± 0.71      F = 0.817              0.445
  Total cholesterol (mg/dL)                                   184.4 ± 4.6   187.4 ± 5.8       182.8 ± 7.7       165.8 ± 12.2     F = 0.511              0.602
  EGFR (mL/min)                                               74.6 ± 3.8    74.9 ± 5.5        72.9 ± 5.3        101.5 ± 34.1     F = 0.707              0.497

Numerical variables expressed as mean ± standard deviation; categorical variables, expressed as n (%);

there was no data on initial NYHA class for one Group DI patient.

DD: deletion/deletion genotype; DI: deletion/insertion genotype; II: insertion/insertion genotype; Follow-up: follow-up duration (months); F: frequency; HF duration: disease evolution since disease diagnosis; BMI: body mass index; NYHA: New York Heart Association; EGFR: estimated glomerular filtration rate.

The idiopathic etiology prevailed (36.0%), followed by the hypertensive (20.7%); however, there was no statistically significant difference in the distribution of the etiologies regarding the GPACE (p = 0.248).

A high percentage of use of major beta-blockers (BB), ACE inhibitors (ACEI) and/or angiotensin-receptor blockers (ARB) was observed, with mean doses close to those recommended by the current Brazilian Guidelines for Heart Failure^[@r32]^. There was no difference concerning the distribution of the type of drugs used according to the GPACE ([Table 2](#t02){ref-type="table"}).

###### 

Medicamentous treatment of the Brazilian population studied according to the genetic polymorphisms of the angiotensin-converting enzyme[\*](#t02-fn01){ref-type="table-fn"}

  **Drug**              **Mean**     **DD (n = 57)**   **DI (n = 49)**   **II (n = 5)**   **Statistical test**   **p Value**
  --------------------- ------------ ----------------- ----------------- ---------------- ---------------------- -------------
  Beta-blocker          108 (98.2)   55 (98.2)         47 (97.9)         5 (100.0)        X^2^ = 0.111           0.946
  Carvedilol            76 (71.0)    34 (61.8)         36 (78.3)         5 (100.0)        X^2^ = 7.471           0.279
  Metoprolol            16 (15.0)    10 (18.2)         4 (8.7)           0 (0)                                   
  Bisoprolol            14 (13.1)    11 (20.0)         5 (10.9)          0 (0)                                   
  Target dose           84.9 ± 3.7   84.3 ± 4.3        84.6 ± 5.8        91.2 ± 32.3      F = 0.78               0.925
  ACEI                  60 (54.1)    30 (52.6)         26 (54.2)         4 (80.0)         X^2^ = 1.394           0.498
  Captopril             6 (10.0)     3 (10.0)          3 (11.5)          0 (0)            X^2^ = 0.513           0.774
  Enalapril             54 (90.0)    27 (90.0)         23 (88.5)         4 (100.0)                               
  Target dose           66.7 ± 3.3   60.4 ± 5.9        71.6 ± 6.4        81.3 ± 1.9       F = 1.233              0.299
  ARB: Losartan         39 (35.1)    22 (38.6)         14 (29.2)         2 (40.0)         X^2^ = 2.158           0.707
  Target dose           73.1 ± 4.3   80.7 ± 10.3       63.3 ± 8.4        62.5 ± 3.8       F = 0.574              0.569
  Espironolactona       74 (66.7)    39 (68.4)         33 (68.8)         2 (40.0)         X^2^ = 1.771           0.413
  Furosemida            79 (71.2)    43 (75.4)         32 (66.7)         3 (60.0)         X^2^ = 1.274           0.529
  Mean dose (mg)        75.4 ± 5.7   80.5 ± 8.0        71.5 ± 8.7        46.7 ± 17.6      F = 0.791              0.457
  Hydrochlorothiazide   26 (23.4)    14 (24.6)         12 (25.0)         \-               X^2^ = 1.624           0.444
  Digitalis             40 (36.0)    25 (43.9)         13 (27.1)         1 (20.0)         X^2^= 3.751            0.153
  Amiodarone            13 (11.7)    6 (10.5)          6 (12.5)          0                X^2^ = 0.746           0.689
  Statins               50 (45.0)    29 (50.9)         17 (35.4)         4 (80.0)         X^2^ = 5.033           0.081
  Allopurinol           18 (16.2)    9 (15.8)          7 (14.6)          1 (20.0)         X^2^ = 0.112           0.946

Numerical variables expressed as mean ± standard deviation; categorical variables, expressed as n (%). DD: deletion/deletion genotype; DI: deletion/insertion genotype; II: insertion/insertion genotype; F: frequency; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin-receptor blocker.

Of the patients studied, 34 (30.6%) had QRS ≥ 120 ms, 38 (34.2%) had LBBB, and 22 (19.8%) had AF on ECG. The distribution of those variables according to the GPACE types was not statistically different.

Eight (7.2%) patients had implantable devices as follows: three (2.7%) had pacemakers; two (1.8%) had implantable cardioverter-defibrillators (ICD); two (1.8%) had undergone cardiac resynchronization therapy (CRT); and one (0.9%) had a combined device (ICD + CRT).

Echocardiographic outcomes
--------------------------

Approximately half of the cohort (49.5%) had severe LV systolic dysfunction when beginning follow-up, with LVEF ≤ 35%. That percentage increased to 58.5% by the end of the study.

[Table 3](#t03){ref-type="table"} shows the echocardiographic data at the beginning and at the end of the study, and the evolution of such measurements. The means of the initial echocardiographic parameters (LVEF, LVSD and LVDD) did not significantly differ between the ACE genotypes. On final echocardiography, only LVSD was significantly different, with a lower mean for the DI GPACE.

###### 

Echocardiographic parameters of the population studied according to the genetic polymorphisms of the angiotensin-converting enzyme

  **Variable[\*](#t03-fn01){ref-type="table-fn"}**   **Total mean**   **DD (n = 57)**   **DI (n = 49)**   **II (n = 5)**   **Statistical test**   **p Value**
  -------------------------------------------------- ---------------- ----------------- ----------------- ---------------- ---------------------- -------------
  initial LVEF (%)                                   34.0 ± 1.0       35.6 ± 1.5        32.1 ± 1.5        34.6 ± 3.4       F = 1.469              0.235
  initial LVSD (mm)                                  54.9 ± 1.0       54.1 ± 1.4        55.7 ± 1.4        55.4 ± 3.0       F = 0.472              0.625
  initial LVDD (mm)                                  65.9 ± 0.9       65.6 ± 1.2        66.1 ± 1.3        66.6 ± 3.1       F = 0.112              0.894
  final LVEF (%)                                     34.3 ± 1.2       32.8 ± 1.6        36.4 ± 1.8        29.4 ± 4.2       F = 1.634              0.200
  final LVSD (mm)                                    56.1 ± 1.3       59.2 ± 1.8        52.3 ± 1.9        59.2 ± 5.2       F = 3.677              0.029
  final LVDD (mm)                                    67.0 ± 1.2       69.4 ± 1.8        64.0 ± 1.8        69.0 ± 4.6       F = 2.197              0.116
  ∆LVEF (%)                                          0.36 ± 1.37      -2.57 ± 14.86     4.62 ± 12.92      -5.20 ± 13.48    F = 3.857              0.024
  ∆LVSD (mm)                                         0.94 ± 1.17      4.60 ± 12.04      -3.73 ± 11.28     3.80 ± 8.70      F = 6.783              0.002
  ∆LVDD (mm)                                         0.82 ± 1.04      3.38 ± 9.90       -2.49 ± 11.47     2.40 ± 5.41      F = 4.026              0.021
  Interval between exams (months)                    65.5 ± 4.3       63.2 ± 6.3        68.0 ± 6.4        65.4 ± 12.4      F = 0.142              0.868

Variáveis numéricas estão expressas em média ± desvio padrão. DD: genótipo deleção/deleção; DI: genótipo deleção/inserção; II: genótipo inserção/inserção; F: frequência; FEVE: fração de ejeção do ventrículo esquerdo; DSVE: diâmetro sistólico do ventrículo esquerdo; DDVE: diâmetro diastólico do ventrículo esquerdo. ∆FEVE: diferença entre a fração de ejeção do ventrículo esquerdo da última e primeira consulta; ∆DSVE: diferença entre o diâmetro sistólico do ventrículo esquerdo da última e primeira consulta; ∆DDVE: diferença entre o diâmetro diastólico do ventrículo esquerdo da última e primeira consulta.

Analyzing the evolutionary behavior of each echocardiographic variable \[difference between the LVEF at the last and first consultation (∆LVEF); difference between the LVSD at the last and first consultation (∆LVSD); and difference between the LVDD at the last and first consultation (∆LVDD)\], the following distinct and significant patterns are observed: on average, DI showed an increase in LVEF as compared to the initial, while DD and II showed a decrease ([Figure 1](#f01){ref-type="fig"}). Regarding the LV size, the DI genotype showed a reduction in LVSD and LVDD at the end of follow-up, while the DD and II genotypes showed an increase in the cavitary diameters ([Figures 2](#f02){ref-type="fig"} and [3](#f03){ref-type="fig"}, respectively).

![Ejection fraction variation between the end and the beginning of follow-up of the population studied according to the genetic polymorphisms of the angiotensinconverting enzyme (ACE). DD: deletion/deletion genotype; DI: deletion/insertion genotype; II: insertion/insertion genotype.](abc-102-01-0070-g01){#f01}

![Left ventricular (LV) systolic diameter variation between the end and the beginning of follow-up of the population studied according to the genetic polymorphisms of the angiotensin-converting enzyme (ACE). DD: deletion/deletion genotype; DI: deletion/insertion genotype; II: insertion/insertion genotype.](abc-102-01-0070-g02){#f02}

![Left ventricular (LV) diastolic diameter variation between the end and the beginning of follow-up of the population studied according to the genetic polymorphisms of the angiotensin-converting enzyme (ACE). DD: deletion/deletion genotype; DI: deletion/insertion genotype; II: insertion/insertion genotype.](abc-102-01-0070-g03){#f03}

The qualitative analysis (increase *versus* decrease) of the ∆LVSD ([Figure 4](#f04){ref-type="fig"}) and of the ∆ LVDD showed a difference between the GPACE with statistical significance for LVSD (p = 0.046), but not for LVDD (p = 0.095): the DD genotype had a greater number of patients with increased LVSD while the DI variant had a greater number of patients with decreased LVSD by the end of the study.

![Evolutionary behavior of the left ventricular systolic diameter of the population studied according to the genetic polymorphisms of the angiotensin-converting enzyme (ACE). DD: deletion/deletion genotype; DI: deletion/insertion genotype; II: insertion/insertion genotype; LVSD: left ventricular systolic diameter.](abc-102-01-0070-g04){#f04}

Discussion
==========

This study describes the relationship between the GPACE variants and the clinical and echocardiographic outcomes in 111 patients with non-ischemic HF, with mean follow-up of 5.4 years (range, 12.0 - 249.7 months). Other international^[@r11],[@r13]^ and national^[@r14],[@r15]^ studies have carried out that analysis; however, this study is the first to assess exclusively non-ischemic HF in a Brazilian population with a mean follow-up time longer than five years.

Two findings of this study are worthy of note. First, the ACE genotypic profile of the population studied differed from that of most of previous publications, with an extremely low proportion of type II GPACE (only 4.5% of the patients). In addition, the echocardiographic evolutionary behavior represented by the variables ∆LVEF, ∆LVSD and ∆LVDD differed between the GPACEs, with worsening of those parameters in the DD genotype.

The low prevalence of the II genotype observed in this study can be related to the characteristics of the population studied, especially their ethnicity. The meta-analysis by Bai et al^[@r04]^, with 2,453 cases of HF of multiple etiologies, included only 6.4% of black individuals and 23.4% of those of Asian origin, while the population of this study consisted of 51% of white individuals, 36% of black, 13% of individuals with mixed heritage and none of Asian ethnicity. The differences in the prevalences of the ACE genotypes found in this study and in the study by Bai et als. were, respectively: 51.4% *versus* 31% for DD; 44.1% *versus* 46% for DI; and 4.5% *versus* 23% for II.

Tiago et al^[@r33]^, studying 157 black individuals with idiopathic HF in South Africa, have reported a GPACE distribution more similar to ours: 45.2% of DD; 38.2% of DI; and 6.5% of II. That might have resulted from the exclusive presence of Afro-descendants in that study. Velloso et al^[@r10]^ have described a similar association of other GPs and the skin color of individuals with HF: the GP prevalences of nitric oxide synthase differed between white and Afro-American individuals.

The different etiologies of non-ischemic HF did not relate to the genetic profile, and the absence of patients with ischemic HF might not have determined higher or lower incidence of any of the genotypes. Amir et al^[@r34]^, studying 195 patients with HF (124 ischemic and 71 non-ischemic), have already demonstrated no significant variation in genotypes regarding etiology.

The analysis of the echocardiographic variables showed a significant difference between the means of final LVSD according to the ACE genotypes. The DD GPACE showed higher means than the DI GPACE: 59.2 mm *versus* 52.3 mm, respectively. The small number of patients with the II genotype limited the analysis for that group. The evolutionary parameters ∆LVEF, ∆LVSD and ∆LVDD differed significantly between the GPACEs, with improvement in the EF and LV diameters (reverse remodeling) in the DI genotype. The DD and II genotypes showed an inverse behavior, with worsening of the EF and of the ventricular diameters (cardiac dilation).

That more severe evolutionary pattern related to the DD GPACE is in accordance with the findings of other authors^[@r16],[@r24]^. The more marked cardiac dilation in those patients relates to the higher neuro-humoral activation, mainly of the RAAS. The GPACEs are responsible for approximately 50% of the variation in ACE levels, the DD genotype being associated with higher levels of that enzyme^[@r35]^. Elevated ACE levels are accompanied by increased synthesis of angiotensin and greater activation of that system^[@r36]^.

However, those results are not uniform. De Groote et al^[@r11]^ have found no difference in the echocardiographic parameters of 199 patients with HF, who had not initiated the BB use. The short interval between exams (only three months after optimization of the BB dose as compared to 65.5 months in this study) might have been insufficient to observe cardiac reverse remodeling in that study. Mahjoub et al^[@r17]^ have not detected echocardiographic differences between the GPACEs, but those authors have chosen a categorical analysis, dividing the sample into two groups according to the LVDD (≥ 69 mm *versus* \< 69 mm), corresponding to higher or lower severity, respectively. The statistical analysis of the present study used the numerical values of the echocardiographic parameters as continuous variables, having, thus, higher discriminatory power.

The clinical profile of each cohort varies between studies. In addition to the already discussed relationship of ethnicity and GPACE prevalence, other factors seem to influence the participation of the *ACE* gene on HF natural history and pathophysiology. One of the major factors is drug treatment.

The percentage of BB use was 98.2%, with a target dose of 84.3% of that recommended, higher than that of most clinical trials^[@r14],[@r18],[@r20]^. The use of ACEI and/or ARB was 91.2%, and that of spironolactone, 68.4%. However, the excellence of that treatment can interfere with the patients\' clinical outcomes, hindering the observation of differences according to GPACE.

McNamara et al^[@r12],[@r13]^ have assessed the pharmacogenetic interaction, observing the use of BB^[@r12]^ and ACEI^[@r13]^ and the GPACEs. The DD genotype was associated with worse clinical and echocardiographic outcome, but the impact of that GP was attenuated by the treatment with BB and ACEI. In other words, for that group of patients, the neuro-humoral block might have neutralized the excessive RAAS activity secondary to the DD GPACE. Thus, under optimized therapy, the three genotypes, DD, DI and II, began to behave in a similar manner regarding clinical outcome.

In another study, the combination of two GPACE genetic variants with the GP in the angiotensin II receptor has shown an independent association with clinical outcomes^[@r37]^.

Thus, the polygenic character described for other physical characteristics, such as height^[@r38]^ or lipid profile^[@r39]^, might also seem to play a role in the HF pathophysiology and in RAAS action. The simultaneous study of multiple GPs in the same population has identified that only combinations of genotypes have been associated with clinical and/or echocardiographic outcomes^[@r19],[@r20]^. A panel of genetic markers might be more efficient in detecting more severely ill individuals than isolated GPs.

The present study has some limitations. First, the relatively small number of individuals studied, especially the reduced number of individuals with the II genotype, hindered a more conclusive data analysis. In addition, data collection from medical records represents, by definition, a limitation. However, it is worth noting that such limitation might have been attenuated by the high quality of the service provided at a well-structured HF clinic, with defined protocols, professional training and regular auditing. Last, because this is also a retrospective study, a selection bias might have occurred with the inclusion of a smaller number of more severely ill patients. However, the II genotype, theoretically more prevalent in less critical patients, had the lowest prevalence, which counteracts that selection bias.

The application of genetics to the HF context has become a potentially interesting and attractive tool for risk and severity stratification, as well as a marker of therapeutic response. The complex genetic architecture, represented by the already known polygenic heritage of other characteristics, illustrates the study difficulty on the subject. However, better understanding that area might have a great impact on medical practice, especially cardiology. Thus, the difficulties observed should not be seen as negative results, but as an incentive for further studies that would fill gaps and develop the knowledge in that important area.

Conclusion
==========

The frequency of alleles and variants of GPACE has differed in most international and also national studies on HF, emphasis given to the small number of individuals with the II variant.

The echocardiographic parameters differed significantly between the GPACE variants. The DD genotype related to a worse echocardiographic outcome over a 5.4-year follow-up.
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